Company Overview
Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.
The Tango labs and offices are located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts.
Summary
The Senior Vice President (SVP) of Market Access is a critical enterprise leader responsible for architecting and executing the overarching market access, patient services, pricing, and distribution vision for Tango Therapeutics. As the company transitions from a research-stage biotech into a fully integrated commercial organization, this executive will define the access roadmap for our pipeline of precision synthetic lethality oral medicines.
Reporting directly to the Chief Commercialization Officer and serving as a key pillar of the Commercial Leadership Team, the SVP will build a world-class market access infrastructure from the ground up. This leader will ensure that the clinical promise of our assets is met with frictionless patient access, optimized commercial value, and sustainable market positioning on a global scale.
Your Role:
Enterprise leadership & Organizational Design
- Architect the Access Function: Design, build, and scale a best-in-class, fully integrated market access organization capable of supporting multiple oral oncology product launches
- Executive Mentorship: Lead, empower, and mentor a high-performing leadership team encompassing critical functions across global value and access, health economics and outcomes research (HEOR), strategic operations, patient services, trade operations, and payer strategy
- Cross-Functional Vision: Serve as the strategic anchor for market access within the C-suite and across the enterprise, ensuring that value demonstration, pricing elasticity, and payer insights are embedded into early-stage asset development and overarching commercial strategy
Strategic Priorities:
Global Value & Health Economics
- Value Proposition Strategy: Champion the enterprise-wide value proposition, directing the strategic generation of Health Economics and Outcomes Research (HEOR) to support compelling, evidence-based narratives for health technology assessments and global payers
- Global Access Alignment: Oversee the integration of U.S. and Ex-U.S. access strategies, ensuring a cohesive global approach to value demonstration and market entry
Pricing, Payer Strategy & Policy
- Innovative Pricing Paradigms: Formulate sophisticated launch pricing, gross-to-net (GTN) strategies, and contracting frameworks that maximize product value and ensure favorable positioning across Commercial, Medicare Part D, and Medicaid segments
- Policy Anticipation & Advocacy: Act as the organization's foremost authority on the evolving healthcare policy landscape (e.g., Medicare Part D redesigns, PBM legislation), proactively steering corporate strategy to mitigate risks and capitalize on market shifts
- Government Pricing Optimization: Deep understanding of government programs and calculations. Proven ability to forecast the structural impacts of federal pricing programs, ensuring access strategies align with long-term portfolio revenue goals
Channel Architecture & Patient Experience
- Strategic Distribution Network: Architect an optimal, scalable specialty pharmacy (SP) and distribution network tailored exclusively for high-value oral oncology therapeutics, balancing network control with broad community oncology access
- Best-in-Class Patient Support: Define the vision for Tango’s Patient Services and hub infrastructure, driving strategies that eliminate access friction, optimize time-to-therapy, and deliver superior patient experience
What You Bring:
Education & Experience
- Bachelor’s degree required; advanced degree (MBA, PharmD, MPH, or related discipline) strongly preferred
- 20+ years of progressive biopharmaceutical experience, with a significant tenure in executive-level market access, pricing, and commercial strategy roles
- Demonstrated enterprise leadership experience, successfully transitioning companies through critical inflection points (e.g., clinical-stage to commercial-stage)
- A proven track record of architecting and leading successful U.S. market access launches for novel oral oncology or rare disease therapies
Core Competencies
- Strategic Acumen: Deep understanding of complex oral oncology treatment paradigms, pharmacy benefit designs, and the financial mechanics of specialty distribution and PBM negotiations
- Visionary Leadership: Exceptional ability to recruit, develop, and inspire a diverse team of senior functional leaders
- Executive Presence: Highly developed communication and negotiation skills, with the ability to influence corporate boards, C-level peers, and top-tier external payer and channel partners
- Financial & Analytical Mastery: Advanced capability in modeling complex gross-to-net scenarios, managing high-stakes contract strategies, and aligning access operations with overarching corporate financial goals
#LI-Hybrid
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
Skills Required
- Bachelor's degree
- Advanced degree such as MBA, PharmD, MPH, or related discipline
- 20 or more years of progressive biopharmaceutical experience
- Significant executive-level experience in market access, pricing, and commercial strategy
- Enterprise leadership experience transitioning companies from clinical-stage to commercial-stage operations
- Track record of successful United States market access launches for novel oral oncology or rare disease therapies
- Deep understanding of oral oncology treatment paradigms, pharmacy benefit designs, specialty distribution, and PBM negotiations
- Ability to recruit, develop, and inspire senior functional leaders
- Advanced communication, negotiation, and executive influence skills
- Advanced capability in gross-to-net modeling, contract strategy, and financial alignment
What We Do
Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
